Tag:
Sun Pharmaceuticals
Latest Headlines
Latest Headlines
Drugs made by Sun Pharma, Cipla recalled in U.S.
Two of India's top drugmakers are grappling with product recalls after regulators in the U.S. spotted signs of impurities in their drugs.
FDA brings Sun's Doxil copy online to fix shortage
Fresh off its cobbled-together solution to a methotrexate shortage, the FDA says it's sewn up an alternate supply of the scarce cancer drug Doxil . The agency has approved a substitute for the...
Wyeth puts $960M squeeze on Sun for Protonix launch
Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ( $PFE ) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's
Sun gets NJ plant back on GMP track, still working on Detroit facility
Sun Pharmaceutical Industries is back on track with the FDA regarding its Cranbury, NJ, manufacturing plant. Results of a June re-inspection found the plant had "an acceptable regulatory status."
Sun exec: Generic firms will face same tough times as innovators
High-flying Indian generics-maker Sun Pharmaceutical says it expects copycat companies to find themselves in the same uncomfortable position as cliff-hanging drug innovators are today beginning in
Sun, Max RFID pilot advances
Max Pharma, a German drug distributor, is rolling out a radio-frequency identification system for tracking Sun Pharmaceutical products. Rollout of the UHF system, which uses Gen 2 RFID tags, follows
Sun to market Merck diabetes drugs in India
Merck's diabetes drugs have found a new champion in Sun Pharmaceutical Industries. As part of a strategic partnership between the two companies, Sun will market Januvia and Janumet under different
Merck teams with Sun Pharma on branded generics
Merck is hooking up with India's Sun Pharmaceutical Industries to make and sell generic drugs in emerging markets. It's the latest example of a major drugmaker teaming up with an emerging-markets
India's Sun scouts U.S. for 'bigger' acquisition
A leading Indian generics maker is looking to boost its U.S. presence significantly. Sun Pharmaceutical is scouting for a U.S. acquisition, Chairman Dilip Shanghvi told Bloomberg. And he's looking
Caraco mulls Sun's offer to go private
After two years of manufactuing issues, Caraco Pharmaceuticals may go private. The company has received a buyout offer from Sun Pharmaceuticals, which already owns 75 percent of Caraco, to acquire
